idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
Researchers at the University Medical Center Göttingen (UMG) have discovered a promising new therapeutic approach for pancreatic cancer. By simultaneously blocking two signaling pathways – PI3Kα/δ and SUMO – cancer cells are eliminated, and the immune system is activated to fight the tumor. The results have been published in the journal Gastroenterology.
Pancreatic cancer, also known as pancreatic ductal adenocarcinoma, is one of the most aggressive types of cancer. Despite advances in modern medicine, survival rates remain very low, and many patients develop resistance to available treatments as tumor cells rapidly adapt through alternative mechanisms. Researchers from the University Medical Center Göttingen (UMG), the Technical University of Munich (TUM), the Georg-Speyer-Haus Frankfurt, and Charité – Universitätsmedizin Berlin have now jointly identified a novel therapeutic strategy that could significantly improve treatment efficacy.
Under the leadership of Priv.-Doz. Dr. Matthias Wirth, head of the research group “Functional Genomics and Therapy Resistance,” and Prof. Dr. Günter Schneider, head of Translational Research, both at the Department of General, Visceral, and Pediatric Surgery at UMG, together with Prof. Dr. Ulrich Keller, Director of the Department of Hematology, Oncology, and Tumor Immunology at Charité – Universitätsmedizin Berlin, the research team demonstrated that simultaneous inhibition of the PI3Kα/δ and SUMO signaling pathways selectively kills pancreatic cancer cells. In animal models, this combination therapy markedly reduced tumor growth and additionally activated the immune system to attack the cancer cells. The research was supported by the Deutsche Forschungsgemeinschaft (DFG), Deutsche Krebshilfe, Hector Stiftungen, Wilhelm Sander-Stiftung und Deutschen Konsortium für Translationale Krebsforschung (DKTK. The results were published in the journal Gastroenterology.
Original publication:
Hazal Köse, Christian Schneeweis, Philipp Putze, Constanza Tapia Contreras, Laura Ferreiro, Leonie Witte, Ilaria Deidda, Frederik Herzberg, Sophie Ebert, Juraj Jakubik, Leoni Moldaner, Jovan Todorovic, Isabelle Träger, Chuanbing Zhang, Uta M. Demel, Elisabeth Hessmann, Marieluise Kirchner, Simone Rhein, Jens Hoffmann, Zuzana Tatarova, Michael Ghadimi, Dieter Saur, Kai Kappert, Phillipp Mertins, Günter Schneider, Ulrich Keller, Matthias Wirth. Targeting mutual dependence of PI3Kα/δ and SUMO signaling in pancreatic cancer. Gastroenterology (2025), DOI: 10.1053/j.gastro.2025.08.018
“Our work shows that only the combined inhibition of both signaling pathways – PI3Kα/δ and SUMO – leads to successful elimination of tumor cells. This represents a highly promising strategy for urgently needed new treatment options,” says Prof. Dr. Günter Schneider, one of the senior authors of the study.
New insights: Targeting two vulnerabilities at once
Pancreatic cancer is characterized by an exceptional resistance to standard therapies. Even new targeted drugs that block specific cancer-related genes often lose their effectiveness quickly, as tumor cells develop compensatory escape mechanisms. The PI3K signaling pathway plays a central role in the development and progression of pancreatic cancer. Previous attempts to therapeutically inhibit this pathway have been largely unsuccessful. Researchers in Göttingen discovered that when the PI3K pathway is blocked, cancer cells compensate by activating another cellular mechanism – SUMOylation. In this process, small proteins called SUMO proteins attach to target proteins, altering their function and stability, thereby helping cancer cells adapt to stress conditions.
“For the first time, we were able to show that these two signaling pathways are mutually dependent. When one is blocked, the cancer cells activate the other as a compensatory mechanism,” explains Prof. Dr. Ulrich Keller, senior author of the study.
“The combination therapy works on multiple levels. It not only directly kills cancer cells but also activates the immune system. Immune cells were able to infiltrate the tumor more effectively and destroy the cancer cells. This dual effect – direct tumor cell death and immune activation – makes the approach particularly promising,” adds Priv.-Doz. Dr. Matthias Wirth, senior author of the study.
A significant therapeutic approach for patients
Further studies will be needed to develop this approach into a clinical therapy. “Our findings reveal that the simultaneous inhibition of PI3K and SUMO uncovers a previously untapped vulnerability of pancreatic cancer,” says Priv.-Doz. Dr. Matthias Wirth.
Priv.-Doz. Dr. Matthias Wirth, Department of General, Visceral, and Pediatric Surgery, Phone +49 551 / 39-65161, matthias.wirth@med.uni-goettingen.de
Hazal Köse, Christian Schneeweis, Philipp Putze, Constanza Tapia Contreras, Laura Ferreiro, Leonie Witte, Ilaria Deidda, Frederik Herzberg, Sophie Ebert, Juraj Jakubik, Leoni Moldaner, Jovan Todorovic, Isabelle Träger, Chuanbing Zhang, Uta M. Demel, Elisabeth Hessmann, Marieluise Kirchner, Simone Rhein, Jens Hoffmann, Zuzana Tatarova, Michael Ghadimi, Dieter Saur, Kai Kappert, Phillipp Mertins, Günter Schneider, Ulrich Keller, Matthias Wirth. Targeting mutual dependence of PI3Kα/δ and SUMO signaling in pancreatic cancer. Gastroenterology (2025), DOI: 10.1053/j.gastro.2025.08.018
Prof. Dr. Günter Schneider, University Medical Center Göttingen (UMG), Prof. Dr. Ulrich Keller, Char ...
Copyright: umg/frank stefan kimmel, charité/wiebke peitz, privat/matthias wirth
below: Mini tumor models from patient-derived tissue, known as organoids, without and with therapy. ...
Copyright: umg/constanza tapia contreras and gsh/zuzana tatarova
Merkmale dieser Pressemitteilung:
Journalisten
Biologie, Medizin
überregional
Forschungsergebnisse, Forschungsprojekte
Englisch
Prof. Dr. Günter Schneider, University Medical Center Göttingen (UMG), Prof. Dr. Ulrich Keller, Char ...
Copyright: umg/frank stefan kimmel, charité/wiebke peitz, privat/matthias wirth
below: Mini tumor models from patient-derived tissue, known as organoids, without and with therapy. ...
Copyright: umg/constanza tapia contreras and gsh/zuzana tatarova
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
